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RINGRAZIAMENTI E DEDICHE
  
III 
SUMMARY 
 
 
 
Prostate cancer is the most commonly diagnosed malignancy in men in 
developed countries. ErbB2 contributes to prostate cancer progression by 
activating the androgen receptor in a steroid poor environment, thus 
promoting androgen-independent cell growth and survival. The consequent 
development of hormone refractory tumors is a major obstacle in prostate 
cancer therapy. 
The inhibition of ErbB2 signal transduction pathways by the use of human 
antibodies has been considered as a valuable alternative strategy for cancer 
therapy. 
Herein we report a comparative analysis of the antitumor effects of three 
different antibodies targeting different epitopes of ErbB2: Herceptin 
(Trastuzumab), 2C4 (Pertuzumab),  and Erb-hcAb, a novel fully human 
compact antibody produced in our laboratory. 
We demonstrate that the in vitro and in vivo growth of both androgen- 
dependent and –independent prostate cancer cells is efficiently inhibited by 
Erb-hcAb, which shows antitumor effects on some cell lines more potent than 
those observed for either Herceptin or 2C4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
IV 
SOMMARIO 
 
 
 
Il cancro della prostata è il tumore maggiormente diagnosticato negli uomini 
nei paesi industrializzati. ErbB2 contribuisce allo sviluppo di malignità 
attraverso il recettore degli androgeni attivato anche in assenza di steroidi, 
promuovendo così la crescita delle cellule tumorali androgeno-indipendenti. 
Il conseguente sviluppo di tumori resistenti alla deprivazione di androgeni è 
uno dei principali ostacoli nella terapia del cancro alla prostata. 
L'inibizione delle vie di trasduzione del segnale di ErbB2 mediante l’impiego 
di anticorpi umani è stata considerata una valida strategia per la terapia del 
cancro. 
In questo lavoro di tesi, sono stati analizzati mediante valutazione 
comparativa gli effetti antitumorali di tre anticorpi che legano diversi epitopi 
di ErbB2: Herceptin (Trastuzumab), 2C4 (Pertuzumab) e Erb-hcAb, un 
nuovo anticorpo compatto completamente umano prodotto nel nostro 
laboratorio. 
Erb-hcAb inibisce efficacemente la crescita in vitro e in vivo di cellule 
tumorali della prostata sia androgeno-dipendenti che androgeno-indipendenti 
con effetti su alcune delle linee cellulari saggiate più potenti di quelli 
osservati per Herceptin o 2C4. 
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1. INTRODUCTION 
 
 
 
Prostate cancer is the second leading cause of cancer death among men 
in the US, where in 2005 it was the most frequently diagnosed cancer, 
accounting for approximately 33% of incident cases in men and 10% of 
deaths (1). Most of the patients with an advanced form of the disease at 
diagnosis are treated by systemic androgen ablation therapy. Initially, the 
cancer is responsive to this type of treatment because it exhibits an androgen-
sensitive phenotype (2). Unfortunately, at a later stage the cancer typically 
progresses in a form that does not respond anymore to further androgen 
deprivation, thus becoming androgen-independent. Androgen-independent 
prostate cancer is resistant to therapeutic interventions and ultimately leads to 
the demise of the patient.  
The mechanisms through which prostate cancer converts to androgen 
independence are still unclear. It has been reported that the onset of ErbB2 
protein overexpression may coincide with the emergence of androgen 
independence as the androgen receptor can be activated by ErbB2 through 
Akt pathway, thus promoting androgen-independent prostate cancer growth 
and survival (3). ErbB (also known as Her2) is a transmembrane tyrosine 
kinase member of the epidermal growth factor receptor (EGFR) family, 
which is overexpressed in many human cancer types. In particular, ErbB2 is 
implicated in malignant transformation and tumorigenesis (4,5), and it is 
overexpressed in breast, ovary, urinary, bladder, prostate and non-small cell 
lung cancer and in several other carcinomas (6,7,8), whereas on normal 
tissues it is not detectable or it is expressed at very low levels. 
Owing to their role in cancer pathogenesis, ErbB2 and EGFR have become 
important targets of anticancer therapy: many drugs have been developed 
against one or both of these receptors.  
Herceptin (Trastuzumab) is the only humanized monoclonal antibody 
available for the treatment of ErbB2-positive breast cancer since 1998 when 
it was approved by FDA, and is now used for the treatment of both metastatic 
and early-stage breast cancer (9). Although Herceptin significantly improves 
the outcome for patients with ErbB2-positive breast cancer, not all the 
patients benefit from the treatment. A significant fraction of the patients do 
not respond at all, and most of the patients who initially respond to Herceptin 
generally tend to develop resistance during the treatment (10).  
Furthermore, also carcinomas with a high expression of ErbB2, such as 
non-small cell lung carcinoma, gastric and prostate tumours, have been found 
to be resistant or much less sensitive to Herceptin treatment (11,12,13). 
Finally, large-scale clinical studies with Herceptin have shown that it 
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engenders cardiotoxicity (14,15). It especially occurs in patients treated 
previously or concurrently with anthracyclines. 
Thus, there is an urgent need to identify new antibodies capable of 
disrupting the ErbB2 signaling pathway in cancer patients. 
Recently, we produced a novel fully human anti-ErbB2 immunoagent, 
engineered by fusing Erbicin, a human anti-ErbB2 scFv, with the Fc region 
of a human IgG1 (16)(Fig.1A).  
The human anti-ErbB2 antibody construct has been called Erb-hcAb 
for its “compact” size (100kDa), compared with the full size (155kDa) of a 
natural IgG. It has been reported that Erb-hcAb is capable of selective 
binding to malignant cells that express ErbB2, and of inhibiting their growth 
in vitro and in vivo, with no effects on ErbB2-negative cells. Moreover Erb-
hcAb is endowed with both ADCC and CDC cytotoxic effects(16,17) 
More recently, it has been shown that Erb-hcAb does not display the 
cardiotoxic effect of Herceptin in vitro on rat cardiomyocytes and in vivo on 
a mouse model, whereas Herceptin was strongly toxic. This difference was 
found to be due to their different mechanism of action, which can explain 
their different effect: Herceptin, at difference with Erb-hcAb, induces 
apoptosis in cardiac cells (18). Finally Erb-hcAb is active in vitro and in vivo 
against some Herceptin-resistant, ErbB2-positive breast cancer cell lines (19).  
In the present study, we investigated the antitumor effects of Erb-hcAb, 
towards androgen-dependent and androgen-independent ErbB2-positive 
prostate cancer cells in comparison with Herceptin and 2C4 the mouse 
antibody version of Pertuzumab, a new humanized anti-ErbB2 monoclonal 
antibody, currently in phase II clinical trials for metastatic breast cancer (20), 
ovarian, prostate and non small-cell lung cancer (21,22). 
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Fig. 1A Schematic representation of Erb-hcAb (C), the human compact anti-
ErbB2 antibody made up of two Erbicin molecules (A) fused to the CH2 and 
CH3 regions of human IgG1 (B). 
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2. MATERIALS AND METHODS  
 
 
 
2.1 Cell cultures and antibodies 
 
 
The hybridoma cells producing 2C4 antibody were grown in DMEM-RPMI-
1640 medium in a 1:1 ratio (Gibco Life Technologies, Paisley, UK BRL).. 
The CHO (Chinese Hamster Ovary) cell line of clone K1, transfected with 
the recombinant plasmid pIgPlus, was cultured in RPMI-1640 medium 
containing neomycin at a concentration of 1 mg/ml. 
The LnCap and PC3 cells lines, were cultured in RPMI-1640 medium  
The Du145 cells,  were cultured in EMEM (Eagle's Minimum Essential 
Medium) containing sodium pyruvate and non-essential amino acids at a 
concentration of 1 mM. The 22Rv1 cells were cultured in DMEM containing 
HEPES at a concentration of 15 mM .All the cell lines were supplemented 
with 10% heat-inactivated foetal bovine serum (FBS), 50 Units/ml penicillin, 
and 50 μg/ml streptomycin (all from Gibco), cultured at 37°C in 5% CO2 
atmosphere. 
The antibodies used were: Herceptin (Genentech, South San Francisco, CA, 
USA); horseradish peroxidase-conjugated goat anti-human affinity isolated 
IgG1 (Fc- specific, Sigma, St Louis, MO, USA), monoclonal anti-human IgG 
(Fc-specific, Sigma), horseradish peroxidase-conjugated goat anti-mouse 
immunoglobulins (Pierce, Rockford, IL, USA) horseradish peroxidase-
conjugated  anti β actin (Pierce).  
 
 
2.2 Production and purification of Erb-hcAb  
 
 
For recombinant protein production, transfected CHO cells were expanded to 
near confluence in selective medium containing neomycin, and then were 
grown for 3–4 days in serum-free medium. The recombinant fusion protein, 
henceforth termed Erb-hcAb, secreted by transfected CHO cells, was purified 
from culture medium by affinity chromatography on a protein A-Ceramic 
Hyper D®F column (BioSepra, Cergy-Saint-Christophe, France) loaded with 
300–500 ml of conditioned medium, washed with 10 volumes of 100 mM 
Tris-HCl, pH 8.0 containing 0.5 M NaCl, and 10 volumes of 10 mM Tris-
HCl, pH 8.0. The protein eluate was obtained with 50 mM glycine pH 3.0, 
and immediately neutralised with 1/10 volume of 1 M Tris-HCl, pH 8.0. 
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2.3 Production and purification of 2C4 
 
 
2C4 hybridoma cells were expanded to near confluence in complete medium, 
and then were grown for 3–4 days in serum-free medium. The secreted 
antibody was purified from culture medium by affinity chromatography on a 
protein G sepharose loaded with 300–500 ml of conditioned medium. Wash 
and elution steps were carried out as described above for Erb-hcAb. 
 
 
2.4 SDS-PAGE and western blotting analyses of Erb-hcAb and 2C4  
antibodies 
 
 
The expression of Erb-hcAb and 2C4 was evaluated by 8% SDS-PAGE 
analyses of conditioned medium, under nonreducing condition, followed by 
electroblotting onto poly-vinylidene difluoride membranes (Millipore 
Corporation, Bedford, MA, USA). For Erb-hcAb detection, was used 
horseradish peroxidase-conjugated anti-human IgG1 (Fc-specific) mAb, 
while for  2C4 detection were used horseradish peroxidase-conjugated goat 
anti-mouse immunoglobulins (Pierce, Rockford, IL, USA) both followed by 
enhanced chemioluminescence (Super signal West Pico, Pierce Rockford, 
IL,USA). 
 
 
2.5 Cell lysis and immunoblotting analyses 
 
 
The cells, washed with PBS, were collected by centrifugation at 1200 rpm for 
7 minutes. The pellet  was resuspended in lysis buffer (10 mM Tris-HCl, pH 
7.4, 0.5% Nonidet P-40, 150 mM NaCl), containing CompleteTM proteases 
inhibitor (Boehringer Mannheim, Germany).  
After 20 min at 0°C, the extracts were clarified by centrifugation at 12.000 
rpm at 4°C for 15 min. Aliquots of 20 μg were run on 7.5% SDS-PAGE, 
followed by electroblotting onto PVDF membranes (Millipore, Bedford, Ma). 
The ErbB2 protein was detected using Neu anti-ErbB2 mAb (Santa Cruz), 
followed by rabbit anti-mouse horseradish peroxidase conjugated antibody. 
The signal intensity of reactive bands was quantitatively measuread by a 
phosphorimager (45-710, Bio Rad, Hercules, CA) 
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2.6 ELISA assays 
 
 
ErbB2-positive prostate tumor cells, harvested in nonenzymatic dissociation 
solution (Sigma), were washed and transferred to U-bottom microtitre plates 
(1 × 10
5
 cells per well). After blocking with PBS containing 6% bovine 
serum albumin (BSA), cells were treated with the antibodies in enzyme-
linked immunosorbent assay (ELISA) buffer (PBS/BSA 3%) for 90 min. 
After centrifugation and removal of supernatants, the pelleted cells were 
washed twice in 200 μl of ELISA buffer, resuspended in 100 μl of ELISA 
buffer, and incubated with peroxidase-conjugated anti-human IgG (Fc-
specific) antibody (Sigma) or peroxidase-conjugated anti-mouse IgG 
antibody (Pierce) for detection of human or mause antibodies, respectively. 
After 1 h, the plates were centrifuged, washed with ELISA buffer, and 
reacted with 3,3′,5,5′-tetramethylbenzidine (TMB) (Sigma). Binding values 
were determined from the absorbance at 450 nm, and reported as the mean of 
at least three determinations (standard deviation 5%). 
 
 
2.7 Cell growth inhibition assays 
 
 
Prostate tumor cells were seeded in 96-well, flat-bottom plates at a density of 
7.5 10
3
well. After addition of the protein under test, viable cells by the 
Trypan blue-exclusion test were counted at suitable time intervals. Cell 
survival was expressed as percent of viable cells in the presence of the 
protein under test with respect to control cultures grown in the absence of the 
protein. Typically, cell survival values were obtained from at least three 
separate experiments in which triplicate counts were determined; standard 
deviations were below 5%. 
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2.8 In vivo antitumour activity 
 
 
In vivo experiments, were performed in collaboration with Prof. P. Laccetti,  
( University Federico II, Naples, Italy)  with 6-week-old male Balb/c Nude 
mice (Charles River laboratories, Calco, Italy). LnCap or PC3 cells (2 × 10
6
) 
were suspended in 0.2 ml sterile PBS and injected subcutaneously (day 0) in 
the right paw. At day 20, when tumours were clearly detectable, Erb-hcAb, 
Herceptin or 2C4  dissolved in PBS were administered to three different 
groups of 5 mice intraperitoneally at doses of 5 mg/kg of body wt for seven 
times at 72 h intervals.  
Another group of control mice was treated with identical volumes of sterile 
PBS. During the period of treatment, tumour volumes (V) were measured 
with calliper and calculated by the formula of rotational ellipsoid V = A × 
B2/2 (A is the axial diameter and B the rotational diameter). SD values were 
<10%. All mice were maintained at the animal facility of the Department of 
Cellular and Molecular Biology and Pathology, University of Naples 
Federico II. The animal experimentations described herein were conducted in 
accordance with the Italian regulation for experimentation on animals.  
 
 
2.9 Pharmacokinetics and Biodistribution of Erb-hcAb 
 
For assessing the pharmacokinetic and biodistribution properties of Erb-
hcAb, in vivo experiments were performed in a mouse model in collaboration 
with Prof. L. Aloj (Nuclear Medicine, IRCCS National Cancer Istitute, 
Fondazione G. Pascale, Naples, Italy). To this aim, CD1 nude mice were 
subcutaneously injected with LnCap cells (1 x 10
6 
cells) in the flank to 
generate xenografts. After 3 weeks tumor weights were in the range of 0.2 to 
0.5 g. Animals were divided into 3 groups of 5 mice each and 
125
I labeled 
Erb-hcAb was injected ip (1-2 E6 cpm/animal). At preset times ranging from 
5 min to 96 h retro-orbital sinus sampling was performed alternating group of 
animals for each time point in order to evaluate blood clearance of the 
radiolabelled antibody fragment. At 96h animals were sacrificed and residual 
activity in organs was determined by gamma counting and weighing. 
Radioactivity levels are expressed as percentage of injected dose per gram 
(%ID/g) normalized for a 20 g mouse. 
The blood clearance parameters of the labeled protein were fitted using Prism 
4.0  software (Macintosh version, GraphPad Software, San Diego California 
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USA, www.graphpad.com) according to the equation: X (t) = A exp (-(alpha 
t)) + B exp (-(beta t)), where X (t) is the %ID/g of radiolabeled antibody at 
time t.  This biexponential blood clearance profile was calculated from the 
time of maximal concentration of blood radioactivity. 
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3. RESULTS 
 
 
 
3.1 Purification of Erb-hcAb and 2C4  
 
 
Erb-hcAb was expressed by CHO (Chinese Hamster Ovary cells) 
transfected with the recombinant plasmid (pIg1plus) containing the cDNA 
encoding Erb-hcAb. 2C4, the parental mouse antibody of Pertuzumab, was 
produced by hybridoma cells (LGC Promochem). Both the antibodies were 
secreted into the culture medium, and purified by affinity chromatography 
(see Materials and Methods) with a final yield of 1,5 mg
 
L
-1
 for Erb-hcAb 
and 3 mg L
-1
 for 2C4. 
The protein concentration was determined by absorbance at 280 nm 
and by Bradford colorimetric assays. 
When the purified fractions of Erb-hcAb and 2C4 were analysed by 
SDS-PAGE (Fig.1), they were found to migrate with the expected molecular 
sizes of about 100 kDa for Erb-hcAb and 155 kDa for 2C4. Western blotting 
analyses of Erb-hcAb and 2C4 performed with an anti-human Fc (Sigma) and 
an anti-mouse mAb (Sigma) demonstrated immunoreactivity of the purified 
proteins (Fig.1). 
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155 KDa   →
1 2 3
100 KDa   →
4 5
 
 
 
 
 
 
Fig. 1. SDS-PAGE and Western blotting analyses of purified 2C4 and 
Erb-hcAb.Coomassie Blue staining of 2C4 and Erb-hcAb fractions eluted by 
affinity chromatografy are in Lane 2 and Lane 3 respectively; Western 
blotting analyses of purified 2C4 and Erb-hcAb are in Lane 4 and in Lane 5 
respectively. Molecular weight standards are in Lane 1.  
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3.2 ErbB2 levels on prostate cancer cells 
 
 
The level of ErbB2 receptor in prostate tumors was investigated by 
Western blotting analyses of cell extracts from four different prostate cancer 
cells lines: Lncap, Du145, Pc3 and 22rv1. Briefly, cells were lysed and 
analyzed by Western blotting with a commercial anti-ErbB2 antibody (Neu, 
Santa Crutz) and an anti-actin mAb. As a positive control, we used SKBR3 
human breast cancer cells, which express high levels of ErbB2. As shown in 
Fig.2, ErbB2 is expressed in all the prostate cell lines tested, even though at 
lower levels with respect to those observed in mammary carcinoma cells. 
 
 
 
 
 
 
 
 
Fig. 2.Western blotting analyses with the anti-ErbB2 (Neu) mAb of the 
expression levels of ErbB2  in the indicated cell lines. To normalize the band 
signals, an anti-actin mAb was used. 
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These results were confirmed by ELISA assays, performed by 
incubating the prostate cancer cells with increasing concentrations of Erb-
hcAb, Herceptin or 2C4. As shown in Fig.3, the three antibodies bind to all 
the prostate cells tested with a comparable affinity even though Herceptin 
shows a lower binding ability on 22RV1 and PC3 cells. 
 
 
 
 
 
 
Fig. 3. Binding curves of the antibodies to prostate cancer cell lines. 
Herceptin (triangles), Erb-hcAb (rhomboids) and 2C4 (squares) were tested 
on DU145 (A), 22RV1(B), LnCap (C) and PC3 (D) cells 
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3.3 In vitro effects of Erb-hcAb on prostate cancer cells 
 
The antitumor effects of the antibodies were tested on ErbB2-positive 
prostate cancer cells by incubating Lncap, Du145, 22RV1 and PC3 cells in 
the absence or in  the presence of increasing concentrations (50-200nM) of 
Erb-hcAb, Herceptin or 2c4. 
After 72 hours, cells were counted and their survival was expressed as 
percentage of viable cells in the presence of the protein under test, with 
respect to control cells grown in the absence of the protein. The SD was 
calculated on the basis of the results obtained from six different experiments. 
As shown in Fig.4, Erb-hcAb was found to selectively inhibit the 
growth of all the cells tested in a dose-dependent manner, showing a stronger 
effect with respect to Herceptin and 2C4, when high protein concentrations 
were tested. 
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Fig. 4. Effects of the antibodies on cell survival. Dose-response curves 
of Herceptin (triangles), Erb-hcAb (rhomboids) and 2C4 (squared) on 
prostate cancer cells: 22RV1 (A), LnCap (B), DU145 (C) and PC3 (D). 
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3.4 In vitro effects of combinationof Erb-hcAb, Herceptin and 2C4 prostate 
cancer cells 
 
On the basis of the observation that Herceptin, Pertuzumab and Erb-
hcAb bind to different epitopes, we investigated whether the combination of 
the three antibodies could allow for more effective and lower therapeutic 
doses. 
To this aim, ErbB2-positive LnCap androgen-dependent and DU145 
androgen-independent prostate cancer cells, were treated for 72 h at 37°C 
with Herceptin (100 nM) or Erb-hcAb (100 nM) or Pertuzumab (100 nM), or 
with a combination of each antibody with the others at the same 
concentrations. As shown in Figure 5, the combinatorial treatment of the 
three antibodies inhibited the growth of prostate tumor cells more effectively 
than the treatment with either each single immunoagent or combination of 
two antibodies (data not shown), thus showing additive effects. 
Fig. 5. Growth inhibition effects on ErbB2-positive prostate cancer 
cells of combinatorial treatments (grey bars) of 2C4 (yellow bars), Erb-hcAb 
(blue bars) and Herceptin (red bars). 
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3.5 In vivo Antitumor Activity of Erb-hcAb 
 
 
For in vivo studies, Erb-hcAb was tested on human prostate,  
LnCap androgen-dependent and PC3 androgen-independent cancer cells. 
As shown in Fig.6, the treatment of mice bearing LnCap and PC3 
tumors with seven doses, at 72h intervals, of 5 mg /Kg
-1 
of
 
body wt of Erb-
hcAb induced a dramatic reduction in tumour volume. In parallel 
experiments, we tested the effects of Herceptin and 2C4, administered as 
indicated above for Erb-hcAb.  
 
Fig. 6. In vivo effects on tumor growth of Erb-hcAb. Mice inoculated 
with 2x105 PC3 (A) or Lncap (B) prostate cancer cells were untreated 
(rhomboids) or  treated with 2C4 (triangles), Herceptin (squares) and Erb-
hcAb (crosses). 
 
 
Surprisingly, 2C4 was found to be effective for PC3 tumors but inactive on 
Lncap androgen-dependent tumors, whereas Herceptin, as expected (20), 
showed only slight effects on both androgen-dependent and androgen-
independent tumors. 
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No growth inhibition was observed in mice treated with PBS. During the 
period of treatment, the animals did not show signs of wasting or other 
visible signs of toxicity. 
 
 
3.6 Pharmacokinetics and Biodistribution of Erb-hcAb 
 
 
Erb-hcAb was labeled with Na 
125
I and injected i.p. (1-2 E6 
cpm/animal) in mice bearing LnCap xenographts. At increasing time 
intervals, ranging from 5 min to 96 h retro-orbital sinus sampling was 
performed to evaluate blood clearance of the radiolabelled compact antibody. 
At 96h animals were sacrificed and residual radioactivity in organs was 
determined by gamma counting and weighing. Radioactivity levels are 
expressed as percentage of injected dose per gram (%ID/g) normalized for a 
weight of 20 g per mouse. 
The blood clearance profile of 
125
I-Erb-hcAb is well described by the 
biexponential function with a rapid early clearance phase and a slower late 
phase (Fig.7). The values found (t1/2 of 7.92 h and 43.62h for the alpha and 
beta phase, respectively) are those expected for radiolabeled proteins of 
similar molecular weight (23) and indicate stability of the immunoconjugate. 
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Fig. 7. Blood clearance profile of 
125
I-Erb-hcAb. The estimated alpha 
and beta rate parameters corresponding respectively to the rapid early and the 
slower late clearance phases are as expected for radiolabeled proteins of 
similar weight.  
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Biodistribution at the 96 h time point showed higher accumulation of 
125
I-
Erb-hcAb in the LnCaP xenografts compared to all the other organs 
measured. These results taken together indicate adequate biodistribution 
properties of the radiolabeled compound due to the extended circulating half-
life which yield high concentrations in the ErbB2 expressing xenografts 
necessary for biological activity.  
 
 
 
 
 
 
 
Fig. 8. Tissue and tumor biodistribution of radiolabeled Erb-hcAb at 
96 h post-injection. The LnCap xenografts retain higher amounts of the 
radiolabeled immunoconjugate compared to all the other organs measured, 
with tumor to normal tissue ratios ranging from 1.5 (tumor to lung ratio) to 
approximately 8 times (tumor to muscle ratio).  
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4. DISCUSSION/CONCLUSIONS 
 
 
Prostate cancer is one of the most common malignancies in men 
in developed countries. The developing and adult prostate is regulated 
by androgens acting through the androgen receptor (AR). High levels of 
AR expression are observed in primary prostate cancer and can be 
detected throughout progression in both androgen-sensitive and 
hormone refractory cancers. The development of androgen-
independence creates a major challenge for treatment of prostate cancer 
patients because the hormone refractory tumor is minimally responsive 
to most of the current treatments, such as the androgen ablation therapy. 
Prostate cancer progression is often associated with alteration of 
growth factor or growth factor receptor expression leading to androgen 
receptor activation. Unlike steroid hormones, growth factors regulate 
cellular responses through binding to membrane receptors. Growth 
factor or cytokine binding initiates a phosphorylation cascade that 
ultimately results in phosphorylation of  transcription factors or 
transcription factor-interacting proteins (24,25). A number of recent 
reports suggest that activation of ErbB kinase axis results in AR 
activation. 
The overexpression of the ErbB family members, particularly 
ErbB2, has been observed clinically in a number of cancer types and it 
is associated with poor prognosis in breast cancer patients (4,5). It is 
possible that increased expression of ErbB2 in prostate carcinomas is 
related to the development of hormone resistance. This is likely due to 
the protection by ErbB2 of prostate cancer cells from the androgen 
ablation therapy, as it allows AR transcription under conditions of 
extremely low levels of circulating hormone. ErbB2 activation of AR 
through Akt has been proposed as a major pathway that promotes 
androgen independent prostate cancer growth (26,27). The mechanisms 
by which ErbB2 is activated in prostate cancer are still unclear, but the 
mutual regulation between androgens and the ErbB2 network could 
contribute to shed light on the coincidence of onset of ErbB2 
overexpression with the emergence of androgen independence. Indeed, 
androgen ablation could promote the survival of some cells by 
stimulating ErbB2 expression that is negatively regulated by androgens. 
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Thus, the use of antibodies capable of inhibiting the ErbB2 
signaling could provide some clinical benefits for prostate cancer 
patients. Despite the advances made by the discovery and 
characterization of Herceptin, the only humanized antibody currently 
used for the treatment of breast cancer, most of the prostate cancer cells 
are less sensitive than breast tumor cells to Herceptin treatment (13) 
and many patients eventually relapse. Consequently, there is a need for 
additional therapeutics directed to the ErbB2 signaling pathway.  
In previous studies it has been shown that Erb-hcAb, a fully 
human compact anti-ErbB2 antibody developed in our laboratory, is 
able to inhibit both in vitro and in vivo the growth of breast cancer cells 
either sensitive (16,17) or resistant to the treatment with Herceptin(19). 
Thus, we tested whether Erb-hcAb could be useful for the treatment of 
prostate cancer by determining its effects on prostate cancer cells in 
vitro and in vivo in comparison with those of Herceptin and 
Pertuzumab (2C4), another anti-ErbB2 antibody currently in clinical 
trials for prostate cancer (21). To this aim, we firstly examined the 
levels of ErbB2 expression on a panel of prostate cancer cells by 
western blotting and measured the binding abilities of the antibodies to 
the receptor by ELISA assays, then we tested their effects on the cells 
in vitro and in vivo in a mouse model.  
Here, we show that Erb-hcAb is able to efficiently inhibit the 
growth of both androgen-dependent and androgen-independent tumor 
cells, with antitumor effects more potent than those observed with 
either 2C4 (Pertuzumab) or Herceptin. 
In particular, the antibody 2C4 (Pertuzumab) significantly 
inhibited the growth of androgen-independent tumor cells but strikingly 
it had no effects on the androgen-dependent tumors, whereas Herceptin, 
as reported in the literature (13), showed only slight antitumor effects 
on both types of tumor cells.  
We then tested whether the combination of these antibodies 
targeting different epitopes of ErbB2 led to more potent antitumor 
effects as it has been previously reported in literature that the 
combination of Herceptin and Pertuzumab as well as the combination 
of Herceptin and Erb-hcAb had synergistic or additive effects on breast 
tumor cells (28,29). Indeed, we found that the combination of the three 
different antibodies was the most effective in inhibiting the in vitro 
growth of prostate cancer cells. 
These results therefore suggest a potential use of Erb-hcAb in the 
immunotherapy of prostate cancer in addition to that of breast cancer 
resistant to the treatment with Herceptin, the antibody currently used in 
the clinic. 
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